4 hours ago
1
Jerome Maurice
Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) added ~10% in the premarket on Wednesday after the company announced a mid-stage trial win for bivamelagon, an experimental therapy for a rare obesity condition called acquired hypothalamic obesity.
Citing topline data from its Phase
English (US) ·